Cytokine Signalling Forum

Publications





October 18

Diminution de la dose de Baricitinib chez les patients atteints de polyarthrite rhumatoïde avec un contrôle durable de la maladie: résultats d'une étude prospective

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto Correia A, Otawa S, Lopez-Romero P, de la Torre I, Rooney TP, Smolen JS.
Ann Rheum Dis. 2019 Feb;78(2):171-178. DOI 10.1136/annrheumdis-2018-213271

In active RA patients, with an inadequate response (IR) to DMARDs who achieve low disease activity (LDA) following baricitinib (BARI) 4 mg treatment, disease control is better maintained with continued BARI 4 mg compared to tapering to 2 mg. The objective of this study was to investigate the effect of BARI tapering in patients achieving sustained disease control with BARI 4 mg. In the long-term extension study RA-BEYOND, patients receiving BARI 4 mg who achieved sustained LDA or remission at two...

Mots clefs: JAK, Baricitinib, Clinical, Phase 3

Traduit par: Noack

September 18

Progression des Dommages Structuraux Chez les Patients Atteints de Polyarthrite Rhumatoïde Précoce Traités par Méthotrexate, Baricitinib ou Barictinib Plus Méthotrexate Selon la Réponse Clinique Dans l'Étude RA-BEGIN de Phase 3

van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszros G, De Leonardis F, De La Torre I, López-Romero P, Schlichting D, Nantz E, Fleichmann R.
Clinical Rheumatology 2018;37:2381–90 DOI 10.1007/s10067-018-4221-0

Patients with active RA and little or no prior DMARD treatment, who achieved sustained clinical responses, were less likely to show structural damage progression, irrespective of treatment. RA-BEGIN was a 52-week double-blind, multicentre Phase 3 trial, which assessed the safety and efficacy of BARI as monotherapy or in combination with MTX versus MTX monotherapy, in RA patients with no or limited prior DMARDs use.1-4 This post-hoc analysis evaluated the structural damage progression in patients...

Mots clefs: JAK, Baricitinib, Clinical, Efficacy

Traduit par: Noack